Debate โบ AUMC response ยท Last reviewed 2026-05-16
Response VUmc / Amsterdam UMC
Summary
Researchers at Amsterdam UMC โ including Annelou de Vries, Thomas Steensma, Maartje van der Loos and Daniel Klink โ have responded to international criticism in various peer-reviewed publications. Their follow-up studies report that most adolescents who start puberty suppression go on to hormones and that few stop; the authors of the 2022 continuation study call the result reassuring, while the authors of the 2020 trajectories study note that it may reflect eligibility criteria that select those highly likely to continue. See also /protocol/current-status-netherlands/.
1. Main publications of the AUMC team (since 2020)
- van der Loos MATC, et al. Continuation of gender-affirming hormones in adolescents and young adults. Lancet Child Adolesc Health. 2022;6(12):869โ75. โ follow-up overview
- van der Loos MATC, et al. Bone mineral density in transgender adolescents treated with puberty suppression and subsequent gender-affirming hormones. JAMA Pediatr. 2023;177(12):1332โ41.
- Brik T, et al. Trajectories of adolescents treated with gonadotropin-releasing hormone analogues. Arch Sex Behav. 2020;49(7):2611โ8.
- de Vries ALC, Richards C, Tishelman AC, et al. Bell v Tavistock and Portman NHS Foundation Trust [2020] EWHC 3274: weighing current knowledge and uncertainties in decisions about gender-related treatment for transgender adolescents. Int J Transgend Health. 2021;22(3):217โ24. โ /debate/legal-cases/
2. Core points of the Dutch response
- Continuation rates: of 720 people in Amsterdam who started hormones after puberty suppression in adolescence, 704 (98%) were still prescribed hormones at the end of data collection (van der Loos 2022; the authors call this reassuring, source). The Cass Review reports that 93% of 707 eligible adolescents progressed from blockers to hormones in the 2023 Amsterdam cohort study (source). In the study of Brik et al. (2020), 87% had started hormones after a median of 0.8 years on GnRHa, and the authors note that eligibility criteria may select those highly likely to continue (source). See /protocol/the-three-phases/.
- Bone density: in 75 people followed through long-term hormone treatment, bone density Z-scores that fell during puberty suppression caught up with pre-treatment levels, except at the lumbar spine in participants assigned male at birth (van der Loos 2023, source).
- Discontinuation/regret: in a cohort of 1,766 children and adolescents, 1.4% stopped GnRHa, mostly because of remission of gender dysphoria (van der Loos 2023, source). On regret, the Dutch Health Council (2026) writes that no definitive conclusions can be drawn because of short follow-up and substantial attrition (source) โ see /debate/detransition-research/.
- Control groups: in the Zembla broadcast of 26 October 2023, Annelou de Vries said that research with a control group "is not an option, because you would be withholding a treatment that you know is extremely important for a group" (translated from Dutch; source).
3. Response to the Cass Review
On 21 May 2024 the European Professional Association for Transgender Health (EPATH) published a response to the Cass Review. EPATH largely agrees with recommendations such as shorter waiting lists, better knowledge sharing and more research, but raises concerns about the feasibility of implementation, equitable access, the evaluation of the underlying evidence and the ethics of care.1
See also
- People register โ de Vries, Steensma, van der Loos, Klink.
- International comparison.
- Timeline.
- Current status Netherlands โ the clinical practice on which AUMC bases its position.
- Changes over time โ how the Dutch protocol has evolved.
- Follow-up studies โ overview โ research publications by the AUMC team.
- Cass Review (2024) โ the focus of the Dutch response.
- Scientific criticism โ criticism to which AUMC responds.
- International spread โ deviations from the Dutch model elsewhere.
- Guidelines Netherlands โ official Dutch guidelines.
- FAQ ยท Glossary ยท For journalists.
Footnotes
- EPATH. EPATH's Response to the Cass Review on Transgender Care for Adolescents. 21 May 2024. epath.eu.